Bayer ownership of xarelto?

Who owns Xarelto (rivaroxaban) and what does Bayer actually control?

Xarelto is a prescription medicine (rivaroxaban) that is marketed by Bayer in many markets. Bayer is also the company most closely associated with the product’s development and commercial ownership/management rights.

Bayer has maintained the Xarelto brand and global commercial presence, including through licensing and commercialization arrangements in some countries and with different partners over time.

Is Xarelto still Bayer’s brand, or did ownership change?

In practice, Xarelto continues to be treated as Bayer’s flagship branded anticoagulant internationally, even though manufacturing, distribution, and licensing terms can vary by country and may involve other companies in specific markets.

Does Bayer own the rights to rivaroxaban outright?

Drug “ownership” can mean different things: patent rights, brand/trademark rights, and marketing/commercial rights. For Xarelto, Bayer is the key rights holder behind the product’s brand commercialization and the intellectual-property portfolio that supports it, but the exact bundle of rights can differ by jurisdiction and by agreement.

If you tell me which country (or whether you mean patents vs. marketing), I can narrow the answer to the specific ownership/rights context you’re asking about.